诺和诺德公布其下一代减肥药最新试验结果后 股价下跌5.4%

新浪财经
10 Mar

周一,丹麦制药巨头诺和诺德(Novo Nordisk)表示,其下一代减肥药CagriSema在68周后帮助患有2型糖尿病的肥胖或超重成年患者体重减轻了15.7%,随后该公司股价下跌了5.4%。诺和诺德生产的减肥药Wegovy广受欢迎。该公司此前曾预测,服用CagriSema的患者体重将减轻25%。在去年12月公布的另一项后期试验结果中,该公司发现,在那次测试中CagriSema帮助患者体重减轻了...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10